| HOME >> BIOLOGY >> TECHNOLOGY |
The decline in "Other markets", a very diverse group whose performance is volatile, was mostly due to exceptional 2008 sales and foreign exchange effects.
HY1 highlights
5 years of research were rewarded in the 1st half-year 2009 with the positive results of the phase III clinical study carried out on the house dust mite desensitization tablet.
Moreover, the mutual recognition procedure for Oralair(R) (grass pollen desensitization tablet) started at an operational level and should lead to registration in most European countries by the end of 2009.
Outlook
The 1st half-year 2009 financial results, to be published on 26 August next after close of trading, should report a slight improvement over the 1st half-year 2008.
We confirm our previously issued full-year guidance of sales growth of about 10% and an operating profit maintained at the same high level as 2008, against a background of strong accompanying R&D investments.
Lastly, the second half-year will be marked by a particularly busy news flow: 3 Oralair(R) phase III studies (US, 3rd year of long-term study, protocol optimization), 1 phase IIb/III study on the birch pollen desensitization tablet, which for the first time includes a recombinant allergen, and 1 phase III Staloral(R) study on asthma, carried out in China.
Shareholders' agenda
The 2009 first half-year results will be presented on 27 August 2009 at 11.30am CET at Le Bristol hotel, 112, rue du Faubourg Saint-Honore, 75008 Paris, France.
A webcast of the meeting will be available both in French and English from 3pm.
ABOUT STALLERGENES
Stallergenes is a European biopharmaceutical company dedicated to
desensitization therapies for the prevention and treatment of allerg
'/>"/>
| SOURCE Stallergenes Copyright©2009 PR Newswire. All rights reserved |